Compare ZYME & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | WD |
|---|---|---|
| Founded | 2003 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2017 | 2010 |
| Metric | ZYME | WD |
|---|---|---|
| Price | $22.16 | $63.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $32.75 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 843.3K | 219.5K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 4.15% |
| EPS Growth | N/A | ★ 20.18 |
| EPS | N/A | ★ 3.37 |
| Revenue | $134,481,000.00 | ★ $1,160,070,000.00 |
| Revenue This Year | $63.10 | $21.20 |
| Revenue Next Year | $93.26 | $10.20 |
| P/E Ratio | ★ N/A | $19.16 |
| Revenue Growth | ★ 116.21 | 17.65 |
| 52 Week Low | $9.03 | $58.60 |
| 52 Week High | $28.49 | $96.00 |
| Indicator | ZYME | WD |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 47.37 |
| Support Level | $22.00 | $60.45 |
| Resistance Level | $23.79 | $65.16 |
| Average True Range (ATR) | 0.88 | 2.00 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 3.90 | 34.05 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.